Latest news

  • 30 May 2024
    SERB Pharmaceuticals appoints Vanessa Wolfeler as CEO to drive next stage of the company’s growth
    SERB appoints Vanessa Wolfeler as its new Chief Executive Officer
  • 20 March 2024
    SERB Pharmaceuticals grants exclusive license to M8 Pharmaceuticals, an Acino company, to bring Voraxaze® (Glucarpidase) to cancer patients in Latin America
    SERB Pharmaceuticals, a global specialty pharmaceutical company, and M8 Pharmaceuticals, an Acino company are collaborating to bring an important drug for cancer patients to Latin America. Under the agreement, M8 Pharmaceuticals is licensed to register, market and commercialize SERB’s supportive oncology product Voraxaze® (glucarpidase) in Latin America.
  • 11 December 2023
    Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)
    Patients receiving glucarpidase had higher adjusted odds of kidney recovery, shorter time to kidney recovery, and a lower mortality rate. West Conshohocken, PA, 11 December 2023: BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without […]

News archive



    You are leaving the global corporate website
    This link will take you to a third-party website, the terms of use and the privacy policy of which may be different. SERB declines all responsibility in that regard and in case of a breach of its privacy policy by the third-party website. Moreover, SERB is not responsible for any information or opinion contained in any third-party website.
    Choose your region